Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A.M. Rein, Bart Scott, David S. SnyderBrady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

Original languageEnglish (US)
Pages (from-to)1572-1611
Number of pages40
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number12
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., Klisovic, R. B., Kropf, P., Mohan, S. R., Oh, S., Padron, E., Podoltsev, N., Pollyea, D. A., Rampal, R., Rein, L. A. M., Scott, B., ... Sundar, H. (2016). Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 14(12), 1572-1611. https://doi.org/10.6004/jnccn.2016.0169